Immunology Report
: Analysis on the Market, Trends, and TechnologiesThe immunology sector commands significant financial momentum, with $236.69 billion in total funding amassed by over 3,411 companies globally. Market projections indicate expansion from USD 109.4 billion in 2024 to USD 342.8 billion by 2034 at a 12.1% CAGR, driven by rising autoimmune disease prevalence and regulatory support for biologics and mRNA vaccines (Immunology Market Growth, Demand Analysis). Cutting-edge diagnostics and AI-driven single-cell profiling are elevating R&D efficiency, while biosimilars grow at a 13.1% CAGR, increasing patient access to immunotherapies.
The last update of this report was 57 days ago. If you spot incomplete or incorrect info, please let us know.
Topic Dominance Index of Immunology
The Topic Dominance Index analyzes the time series distribution of published articles, founded companies, and global search data to identify the trajectory of Immunology relative to all known Trends and Technologies.
Key Activities and Applications
- Development and commercial rollout of monoclonal antibodies, with USD 49.9 billion in expected revenue by 2025, addressing rheumatoid arthritis, psoriasis, and inflammatory bowel disease needs (Immunology Market Poised for Growth, Expected to Hit USD 246.04 Billion by 2032).
- Advanced immuno-oncology research deploying immune checkpoint inhibitors and mRNA vaccine platforms to enhance survival rates in cancer patients.
- Expansion of immunoassays, particularly immunohistochemistry (IHC), to enable precise biomarker detection in oncology diagnostics, propelled by a rising global cancer burden (Immunohistochemistry Market Size, Share and Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2025-2034).
- Integration of AI-powered computational immunology for reverse vaccinology and immune response modeling, accelerating target identification and therapeutic design (Immunoinformatics Market Size, Share & Trends Analysis Report, 2019 To 2025).
- Microbiome-based immunomodulation to restore checkpoint inhibitor sensitivity, led by live biotherapeutic products targeting gut-tumor immune cross-talk.
Emergent Trends and Core Insights
- Personalized immunotherapies guided by neoantigen profiling and deep T-cell repertoire mapping, shifting treatment from one-size-fits-all to patient-specific protocols.
- Rapid uptake of immunology biosimilars, growing at a 13.1% CAGR, reducing therapy costs and broadening access in emerging markets (Immunology Biosimilars Market Insights 2025).
- Asia-Pacific surging as a high-growth region, with healthcare spending and autoimmune disease incidence fueling market share to 20.8% by 2025 (Immunology Drug Market Report 2025 (Global Edition)).
- AI-driven antigen prediction and epitope mapping, optimizing vaccine design and accelerating preclinical cycle times.
- Convergence of immunogenomics and digital biomarkers to stratify patients and monitor therapeutic response in real time.
Technologies and Methodologies
- Monoclonal antibody engineering, leveraging recombinant platforms and high-throughput screening to enhance affinity and specificity.
- Bispecific antibodies and antibody-drug conjugates, harnessing dual-target engagement and targeted cytotoxic delivery, supported by 16,762 patents in the immunotherapy domain.
- CAR-NK and CAR-T cell therapies, employing cell-based immunotherapy protocols to reprogram innate and adaptive immunity against tumors.
- Single-cell RNA sequencing and AI-driven analytics for immune cell atlas construction, enabling precision medicine approaches.
- Live biotherapeutic products targeting the gut microbiome to modulate systemic immune checkpoints and overcome primary resistance, as demonstrated by clinical-stage microbiota oncology programs.
Immunology Funding
A total of 654 Immunology companies have received funding.
Overall, Immunology companies have raised $231.5B.
Companies within the Immunology domain have secured capital from 2.6K funding rounds.
The chart shows the funding trendline of Immunology companies over the last 5 years
Immunology Companies
- EverImmune: A live biotherapeutics pioneer harnessing gut microbiota to restore immune checkpoint inhibitor efficacy in cancer patients. Its Oncobax AK platform delivers oral adjuvants that reprogram antitumor immunity in primary resistance settings. The company is rooted in Gustave Roussy research and backed by EU-funded ONCOBIOME collaborations.
- Neobe Therapeutics: Engineering tumor-colonizing bacteria via synthetic biology to disrupt immunosuppressive microenvironments, turning “cold” tumors into immune-infiltrated sites. This strategy aims to enhance responsiveness to existing immunotherapies while minimizing systemic toxicity.
- Stimunity: Institut Curie spin-out developing biopharmaceuticals to activate stalled immunotherapies in non-responding cancer patients. Its lead programs focus on novel immunomodulators that boost innate and adaptive arms, positioning it to address checkpoint inhibitor refractory cases.
- ImmunoGenomics: CLIA-licensed molecular diagnostics lab specializing in exploratory immunoassay platforms and biomarker development. The company supports pharmaceutical partners in assay selection for early-stage drug discovery and translational research.
- CytoImmune Therapeutics: Clinical-stage innovator with the CoalesceNT platform combining bispecific antibodies and CAR constructs to coordinate NK and T-cell activation. By synchronizing innate and adaptive responses, it seeks to shorten treatment timelines and deliver dynamic antitumor immunity.
TrendFeedr’s Companies tool is an exhaustive resource for in-depth analysis of 3.6K Immunology companies.
3.6K Immunology Companies
Discover Immunology Companies, their Funding, Manpower, Revenues, Stages, and much more
Immunology Investors
The TrendFeedr’s investors tool features data on 2.6K investors and funding activities within Immunology. This tool makes it easier to analyze complex investment patterns and assess market potential with thorough and up-to-date financial insights.
2.6K Immunology Investors
Discover Immunology Investors, Funding Rounds, Invested Amounts, and Funding Growth
Immunology News
Stay ahead of the curve with Trendfeedr’s News feature. The tool provides access to 11.3K Immunology. Navigate the current business landscape with historical and current Immunology data at your fingertips.
11.3K Immunology News Articles
Discover Latest Immunology Articles, News Magnitude, Publication Propagation, Yearly Growth, and Strongest Publications
Executive Summary
The immunology landscape is at a pivotal growth juncture, underpinned by massive funding inflows and an expanding roster of specialized companies. Market forecasts anticipate sustained double-digit CAGR driven by unmet needs in autoimmune, infectious, and oncology indications. Breakthroughs in monoclonal antibodies, cell therapies, and computational immunology are converging to deliver highly personalized interventions. Regional expansion in Asia-Pacific and the rise of biosimilars signal broader patient access. For stakeholders, prioritizing AI-enabled discovery, live biotherapeutics, and next-generation diagnostics will be critical to capturing value in this rapidly evolving field.
If you’re an expert in trends or emerging tech, we invite you to contribute to our insights.
